This Is MS Multiple Sclerosis Knowledge & Support Community

I didnt have the rash but I had body-wide itching that lasted about a year. I went to the dermatologist and they couldnt figure out a cause outside of a possible side effect from the Campath. The heat would make it worse but in the shower the beading of very hot water on my skin gave me some relief ...

Thank you for keeping the post going, everyone. I was part of the original cohort of Campath patients givin the high-dose Campath. I was diagnosed with MS in June 2003 and was enrolled in the Campath trial the next month at Stony Brook Hospital NY. I received two full infusions of Campath spaced one...

Genzyme's Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA CAMBRIDGE, Mass., Jun 14, 2010 (BUSINESS WIRE) -- Genzyme Corporation /quotes/comstock/15*!genz/quotes/nls/genz (GENZ 49.50, +0.45, +0.92%) announced today that its alemtuzumab for multiple sclerosis developme...

If and when they approve Campath late next year I fear the price of a round of treatment will jump from $5,000 to $25,000, especially since Genzyme would not be making much money on an MS treatment that only has to be used two years in a row every 4 years (and maybe even every 5-6 years). Shareholde...

The likelihood of your counts jumping that much are minimal but possible. If and when they approve Campath late next year I fear the price of a round of treatment will jump from $5,000 to $25,000, especially since Genzyme would not be making much money on an MS treatment that only has to be used two...

Thats one hell of a one-two punch! Both potent approaches! I dont see the MS standing a chance against that kind of attack! Good luck!!!

I just posted the official company release of this information! These are some pretty amazing numbers never before seen for any MS treatment. I'm really shocked that NO ONE has posted any replies to your post yet. I was in the original cohort Campath study and received two infusions of Campath and h...

Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme's Phase 2 Trial Remain Free of Clinically-Active Disease Apr 14, 2010 (BUSINESS WIRE) -- Genzyme Corporation /quotes/comstock/15*!genz/quotes/nls/genz (GENZ 53.58, -0.06, -0.11%) today reported four-year follow-up data from its c...